Evidence base: Ovarian cancer

A summary of the evidence behind the diagnosis, staging and management of ovarian cancer

Hysterosalpingogram showing ovarian cancer (Photograph: SPL)
Hysterosalpingogram showing ovarian cancer (Photograph: SPL)

Clinical trials

  • Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10(4): 327-40.

Initial results reported the multimodal screening group had a significantly (p <0.0001) improved specificity of 99.8% and a similar sensitivity of 89.4% compared with the USS group. Almost 50% of invasive malignancy detected was stage 1 and 2 (compared with 20-30% in the general population).

It is now widely accepted that ovarian cancer is not one disease but a collective term for invasive cancers originating from different tissues but presenting as ovarian or pelvic tumours.

Studies have determined distinct molecular subtypes within the same histological group which are also associated with clinical endpoints such as disease progression and survival.



 Contributed by Miss Jane Borley and Miss Sadaf Ghaem-Maghami



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in